Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
Sponsor: UMC Utrecht
Summary
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Official title: Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2025-06-01
Completion Date
2028-06-01
Last Updated
2025-12-18
Healthy Volunteers
No
Conditions
Interventions
Dupilumab
In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.
Locations (1)
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands